Real-world evidence on the efficacy and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pylori treatment in elderly patients

Table 2 Characteristics of patients undergoing first-line treatment with successful and failed eradication, n (%)

Characteristic	Total, n = 250	VA success, n = 239	VA failure, n = 11	P value
Age in years	65.3 ± 4.4	65.4 ± 4.4	63.4 ± 4.1	0.1500
Range	60-82	60-82	60-72
Sex as M/F	106/144	103/136	3/8	0.3600
Body weight in kg	65.5 ± 11.3	65.4 ± 11.1	67.4 ± 14.4	0.6400
BMI in kg/m2	24.0 ± 3.4	23.99 ± 11.1	24.8 ± 3.7	0.5000
Cigarette smoking	31 (12.4)	30 (12.5)	1 (9.1)	1.0000
Alcohol drinking	35 (14.0)	34 (14.2)	1 (9.1)	1.0000
Family history of gastric cancer	15 (6.0)	14 (5.9)	1 (9.1)	0.5000
Endoscopy diagnosis
Gastritis	193 (77.2)	183 (76.6)	10 (90.9)	0.7000
CSG	108 (43.2)	105 (43.9)	3 (27.3)	0.3500
CAG	85 (34.0)	78 (32.6)	7 (63.6)	0.0490a
Peptic ulcer	51 (20.4)	50 (20.9)	1 (9.1)	0.4700
Gastric ulcer	14 (5.6)	14 (5.9)	0	1.0000
Duodenal ulcer	27 (10.8)	26 (10.9)	1 (9.1)	1.0000
Complex (gastric and duodenal) ulcer	10 (4.0)	10 (4.2)	0	1.0000
Gastric cancer	1 (0.4)	1 (0.4)	0	1.0000
MALToma	3 (1.2)	3 (1.3)	0	1.0000
Gastric hyperplastic polyp	2 (0.8)	2 (0.8)	0	1.0000
Combined diseases	1.8 ± 1.4	1.8 ± 1.4	1.5 ± 1.4	0.4300
0	53 (21.2)	50 (20.9)	3 (27.3)	0.7100
1	61 (24.4)	57 (23.8)	4 (36.4)	0.4700
2	64 (25.6)	63 (26.4)	1 (9.1)	0.3000
≥ 3	72 (28.8)	69 (28.9)	3 (27.3)	1.0000
Combined medicine	1.3 ± 1.6	1.4 ± 1.6	0.7 ± 1.2	0.1100
0	99 (39.6)	92 (38.5)	7 (63.6)	0.1200
1	59 (23.6)	57 (23.8)	2 (18.2)	1.0000
2	40 (16.0)	40 (16.7)	0	0.2200
≥ 3	52 (20.8)	50 (20.9)	2 (18.2)	0.1300
Comorbidity
Hypertension	89 (35.6)	86 (36.0)	3 (27.3)	0.7500
Diabetes mellitus	45 (18.0)	44 (18.4)	1 (9.1)	0.6900
Hyperlipidemia	88 (35.2)	85 (35.6)	3 (27.3)	0.7500
Heart disease	32 (12.8)	32 (13.4)	0	0.3800
Lung disease	10 (4.0)	10 (4.2)	0	1.0000
Liver disease	28 (11.2)	26 (10.9)	2 (18.2)	0.3500
Renal disease	13 (5.2)	12 (5.0)	1 (9.1)	0.4500
Cerebrovascular disease	10 (4.0)	10 (4.2)	0	1.0000
Autoimmune disease	24 (9.6)	22 (9.2)	2 (18.2)	0.2900
Hypersensitivity disease	4 (1.6)	4 (1.7)	0	1.0000
Malignant tumor	25 (10.0)	22 (9.2)	3 (27.3)	0.0900
Compliance	246 (98.4)	238 (99.6)	8 (72.7)	0.0003c
Adverse events	23 (9.2); 95%CI: 6.2%-13.4%	21 (8.8)	2 (18.2)	0.2900
Eradication rate	95.6% (239/250); 95%CI: 93.0%-98.1%

^aP < 0.05.

^cP < 0.001.

Data are mean ± SD unless otherwise indicated. Cigarette smoking was defined by consumption of > 5 cigarettes a day or > 1 cigarette pack/week consumed in the past 6 months. A family history of gastric cancer was defined as a gastric cancer diagnosis in a first-degree relative (such as a parent, sibling, or child). Alcohol drinking was defined by > 50 g of alcohol/day consumed in the past 6 months. Compliance was defined by > 80% of tablets taken as instructed. BMI: Body mass index; CSG: Chronic superficial gastritis; CAG: Chronic astrophic gastritis; F: Female; M: Male; MALToma: Mucosa-associated lymphoid tissue lymphoma; VA: Vonaprazan-amoxicillin.